AR and prostate carcinoma: Prostate cancer cell lines VCaP, LNCaP, and C4–2B were treated with SBHA and VCaP; LNCaP was treated with RGFP966, resulting in increased acK609-AR upon HDAC1/3 inhibition (Fig. 1C and fig.